Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors.
In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo.
In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.
In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, the role pharma should be playing in helping to ensure patients have access to health insights they can trust.
Results from a Phase III study in pediatric patients demonstrated that Odactra reduced the total combined rhinitis score by 22% compared to placebo.
In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.
In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, shares some best practices on finding trustworthy and verified information about a new prescription or medical device.
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients with bipolar I disorder.
In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.
Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from gastroschisis surgery.
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and neck squamous cell carcinoma.
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
Launching this month, Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well as for the prevention of Marek disease and infectious bursal disease.
Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
Former leaders of the CDC, FDA, and other agencies condemned the layoffs.
James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions.
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Vimkunya is the first FDA-approved vaccine for chikungunya in patients over 12 years of age.
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
John Arena, interim president of global pharma services at Cencora, discusses how companies can continue to develop launch strategies while taking potential regulatory changes into consideration.
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
The latest news for pharma industry insiders.
James Foster, CEO and co-founder of Virax Biolabs, discusses how companies can strategize despite hard-to-predict regulatory headwinds.
